No impact of rifamycin selection on tuberculosis treatment outcome in HIV coinfected patients.
AIDS
; 27(3): 481-4, 2013 Jan 28.
Article
em En
| MEDLINE
| ID: mdl-23014518
ABSTRACT
Rifabutin has been substituted for rifampicin when treating tuberculosis (TB)/HIV coinfection. However, despite reports of anti-TB treatment failure and acquired rifamycin resistance, long-term clinical outcome data are lacking. Observational analyses performed in a UK TB/HIV cohort demonstrated no difference in severe adverse events, anti-TB treatment completion, relapse frequency or subsequent rifamycin resistance when rifampicin and rifabutin were compared, using different combinations of antiretroviral therapy. Our data support the wider use of rifabutin in TB/HIV coinfection.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Rifamicinas
/
Tuberculose Pulmonar
/
Infecções Oportunistas Relacionadas com a AIDS
/
Rifabutina
/
Antituberculosos
Tipo de estudo:
Observational_studies
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
AIDS
Assunto da revista:
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
Reino Unido